An oral prostate cancer RIPTACtherapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC).

Authors: Katherine J. Kayser-Bricker, Andrew J. Armstrong, Johann S. De Bono, Xin Gao, Joseph W. Kim, Michael J. Morris, Matthew Raymond Smith, Kanak Raina, Aaron (Ron) Weitzman, Hope Meely, Paul Ehrlich, Katherine Kacena, Peter Rix, Kyle J. Eastman, James J. Mousseau, Matthew A. Perry

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5115

Source: Full article

---

Abstract

TPS5115